Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002924 · ClinicalTrials.gov registry record · Phase 2
Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)
A Phase 2 study, sponsored by Endocyte.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT01002924: Completed Phase 2 study, sponsored by Endocyte.
NCT01002924 is a Phase 2 study that has completed, run by Endocyte. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01002924, a Phase 2 study, has completed, sponsored by Endocyte.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This extension protocol is for those subjects that have completed the allowed duration of participation in an Endocyte-sponsored clinical trial of EC145 (vintafolide) and have continuing evidence of clinical benefit (stable disease or better) at the time that they completed participation in that study.
Interventions
- DRUG EC145
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-12-31 |
| Est. Completion | 2013-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01002924
The ClinicalTrials.gov registry entry for NCT01002924 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endocyte, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EC145 is the first listed.
NCT01002924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01002924 about?
NCT01002924 is a clinical study titled "Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010)". This extension protocol is for those subjects that have completed the allowed duration of participation in an Endocyte-sponsored clinical trial of EC145 (vintafolide) and have continuing evidence of clinical benefit (stable disease or better) at the time that they completed participation in that stu...
What is the current status of trial NCT01002924?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2009-12-31. Estimated completion is 2013-12-11.
What interventions are being tested in trial NCT01002924?
The interventions under investigation include: EC145 (DRUG).
Who is sponsoring clinical trial NCT01002924?
This trial is sponsored by Endocyte, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.